What is it about?
Kidney Impairment is assoxciated with α-Synucleinopathy (e.g., Parkinson's Disease and Lewy Body dementia). Potential mechanisms underlying this association are discussed, as well as potential use of AChEIs to mitigate symptom progression.
Featured Image
Why is it important?
The synthesis of data on the paper suggest that the use of AChEIs can slow and/or mitigate the deverlopment of α-Synucleinopathy in the CNS.
Perspectives
This paper suggests potentail mechanisms for α-Synucleinopathy and its relationship to renal functioning, as well as potential methods for symptom mitigation.
Dr. Charles M Lepkowsky
Read the Original
This page is a summary of: Kidney Impairment and α-Synucleinopathy: Implications for Assessment and Treatment, The American Journal of Geriatric Psychiatry Open Science Education and Practice, December 2025, Elsevier,
DOI: 10.1016/j.osep.2025.10.001.
You can read the full text:
Contributors
The following have contributed to this page
